



Announcement Summary

Entity name

TELIX PHARMACEUTICALS LIMITED

Announcement Type

New announcement

Date of this announcement

Thursday March 05, 2026

The +securities to be quoted are:

+Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted

Total number of +securities to be quoted

ASX +security code	Security description	Number of +securities to be quoted	Issue date
TLX	ORDINARY FULLY PAID	29,583	02/03/2026
TLX	ORDINARY FULLY PAID	25,249	23/02/2026
TLX	ORDINARY FULLY PAID	8,385	05/03/2026

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type

ACN

Registration number

616620369

1.3 ASX issuer code

TLX

1.4 The announcement is

New announcement

1.5 Date of this announcement

5/3/2026

For personal use only



Part 2 - Type of Issue

2.1 The +securities to be quoted are:

+Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted

2.2 The +class of +securities to be quoted is:

Additional +securities in a class that is already quoted on ASX ("existing class")

For personal use only



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Existing +securities converting into additional +securities in an existing class

FROM (Existing Class)

ASX +security code and description

TLXAL : OPTION EXPIRING 27-JAN-2026 EX \$4.38

TO (Existing Class)

ASX +security code and description

TLX : ORDINARY FULLY PAID

Please state the number of options that were exercised or other +convertible securities that were converted

29,583

The first date the options were exercised or other +convertible securities were converted

12/1/2026

The last date the options were exercised or other +convertible securities were converted

2/3/2026

Is this all of the options or other +convertible securities on issue of that type (ie have all of those options now been exercised or have all of those convertible securities now been converted)?

Yes

The right of the holder of the options or other +convertible securities to receive the +underlying securities is being satisfied by:

An issue of new +securities

The underlying +securities being received by the holder are:

Intended to be, but are not yet, quoted by ASX

Were the options being exercised or other +convertible securities being converted issued under an +employee incentive scheme?

Yes

Are any of the options being exercised or other +convertible securities being converted held by +key management personnel (KMP) or an +associate?

No

Issue date

2/3/2026

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

For personal use only



Issue details

Number of +securities to be quoted

29,583

Are the +securities being issued for a cash consideration?

Yes

In what currency is the cash consideration being paid? What is the issue price per +security?

AUD - Australian Dollar

AUD 4.38000000

Any other information the entity wishes to provide about the +securities to be quoted**Existing +securities converting into additional +securities in an existing class****FROM (Existing Class)****ASX +security code and description**

TLXAO : SHARE APPRECIATION RIGHTS

TO (Existing Class)**ASX +security code and description**

TLX : ORDINARY FULLY PAID

Please state the number of options that were exercised or other +convertible securities that were converted

52,070

The first date the options were exercised or other +convertible securities were converted

23/2/2026

The last date the options were exercised or other +convertible securities were converted

23/2/2026

Is this all of the options or other +convertible securities on issue of that type (ie have all of those options now been exercised or have all of those convertible securities now been converted)?

No

The right of the holder of the options or other +convertible securities to receive the +underlying securities is being satisfied by:

An issue of new +securities

The underlying +securities being received by the holder are:

Intended to be, but are not yet, quoted by ASX

Were the options being exercised or other +convertible securities being converted issued under an +employee incentive scheme?

Yes

Are any of the options being exercised or other +convertible securities being converted held by +key management personnel (KMP) or an +associate?

No

Issue date

23/2/2026

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes



Issue details

Number of +securities to be quoted

25,249

Are the +securities being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Shares issued from exercise of vested NED SARs (former NED) under Telix EIP valued according to independent Black Scholes methodology disclosed in the AGM Notice of Meeting held 18 May 2022.

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

4.950000

Any other information the entity wishes to provide about the +securities to be quoted

Refer <https://ir.telixpharma.com> for AGM Notice of Meeting held 18 May 2022.

Existing +securities converting into additional +securities in an existing class**FROM (Existing Class)****ASX +security code and description**

TLXAV : DEFERRED SHARE RIGHTS US 2024

TO (Existing Class)**ASX +security code and description**

TLX : ORDINARY FULLY PAID

Please state the number of options that were exercised or other +convertible securities that were converted

8,385

The first date the options were exercised or other +convertible securities were converted

2/3/2026

The last date the options were exercised or other +convertible securities were converted

5/3/2026

Is this all of the options or other +convertible securities on issue of that type (ie have all of those options now been exercised or have all of those convertible securities now been converted)?

No

The right of the holder of the options or other +convertible securities to receive the +underlying securities is being satisfied by:

An issue of new +securities

The underlying +securities being received by the holder are:

Intended to be, but are not yet, quoted by ASX

Were the options being exercised or other +convertible securities being converted issued under an +employee incentive scheme?

Yes

Are any of the options being exercised or other +convertible securities being converted held by +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates who are exercising options or converting convertible securities

Name of KMP	Name of registered holder	Number of options being exercised or other +convertible securities being converted
Darren Patti	Darren Patti	804



Issue date

5/3/2026

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Issue details

Number of +securities to be quoted

8,385

Are the +securities being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Shares issued from exercise of vested deferred share rights (2024 SRs) to Telix US domiciled employees. Refer Appendix 3G dated 5 June 2025.

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

0.000000

Any other information the entity wishes to provide about the +securities to be quoted

Telix ordinary shares to be delivered as American Depositary Shares. For further details refer to the Remuneration report in Telix 2024 and 2025 Annual Reports accessible at <https://ir.telixpharma.com>



Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

ASX +security code and description	Total number of +securities on issue
TLX : ORDINARY FULLY PAID	338,840,266

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL	80,000
TLXAR : PERFORMANCE RIGHTS	9,965,235
TLXAP : SHARE RIGHTS	1,220,004
TLXAO : SHARE APPRECIATION RIGHTS	15,239,149
TLXAT : CONVERTIBLE NOTES	3,250
TLXAM : OPTION EXPIRING 20-JUL-2026 EX \$5.37	208,397
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL	100,000
TLXAU : DEFERRED SHARE RIGHTS EX-US 2024	10,561
TLXAV : DEFERRED SHARE RIGHTS US 2024	1,957
TLXAW : PERFORMANCE SHARE APPRECIATION RIGHTS US 2025	4,352,537
TLXAL : OPTION EXPIRING 27-JAN-2026 EX \$4.38	0
TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS	440,000